[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Goldman, Butterwick, Fitzpatrick and Groff\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":271},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,50,80,107,129,155,175,198,218,247],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100635893","evaluate-the-safety-and-efficacy-of-age-serum-in-post-menopausal-patients-on-hormone-replacement-therapy-taking-glucagon-like-peptide-1-agonist-100635893",false,"NCT07558603","Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist","A Prospective, Single Center, Open-label Study Evaluating the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonists","Inclusion Criteria:\n\n1. Post-menopausal women (25 on HRT, 25 non HRT all must be post-menopausal)\n2. Presence of mild to moderate signs of facial aging (e.g., fine lines, laxity, dull texture) based on modified Griffith scale.\n3. Adult women aged 45-65 years.\n4. Fitzpatrick skin types I-VI.\n5. Current treatment with a stable dose of any GLP-1 agonist medication, including Ozempic, Rybelsus, or Wegovy for at least the last 3 months\n6. Must be willing to sign a photography release and ICF,and complete the entire course of the study.\n7. Subjects in good general health based on the investigator's judgment and medical history.\n\nExclusion Criteria:\n\n1. Non post-menopausal state.\n2. Any uncontrolled systemic disease.\n3. History of autoimmune connective tissue disease.\n4. Current use of immunosuppressive medication.\n5. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.\n6. Active dermatitis or active infection in the proposed treatment area.\n7. Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment.\n8. Microneedling treatments of the face and neck during the 1 month period before study treatment\n9. Laser and light based device treatments of the face and neck. Ablative lasers 6-month period before study treatment, and 3-month period for non-ablative lasers.\n10. Any neurotoxin injection to the face or neck during the 6-month period before study treatment\n11. Subjects using any treatment skincare products must discontinue use of these products 2 weeks before the start of participating in this clinical study and for the duration of the study.\n12. Subjects with scarring in the treatment areas, which in the opinion of the investigator could impact results. Subjects with a history of keloids will be excluded.\n13. Subjects who spray tanned or used sunless tanners in the treatment areas 1-month prior to study treatment.\n14. History of connective tissue disease (e.g., lupus, scleroderma), history of Bell's Palsy, history of smoking.\n15. Inability to ambulate following the procedure.\n16. Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study.\n17. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.",true,"FEMALE","45 Years","65 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","The primary objective is to assess the safety and efficacy of the AGE Serum in improving the appearance of skin in post-menopausal subjects on HRT and non-HRT who are takingGLP-1 agonist therapy through the use of investigator assessments, subject questionnaires\u002Fassessments, photography, skin imaging, and reported adverse reactions.",[28],"Laxity; Skin",[30,31,32,33,34,35,36],"GLP1","HRT","Hormone replacement therapy","weight loss","skin laxity","skin texture","skin tone","NOT_YET_RECRUITING","2026-04-24",{"date":40,"type":41},"2026-04-30","ACTUAL",{"date":43,"type":22},"2026-04-20",{"date":45,"type":22},"2026-11-30",{"name":47,"class":48},"Goldman, Butterwick, Fitzpatrick and Groff","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":16,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100628507","phase-2-assess-efficacy-of-a-nanodiamond-periprocedural-skin-care-regimen-for-ablative-resurfacing-100628507","NCT07462533","Assess Efficacy of a Nanodiamond Periprocedural Skin Care Regimen for Ablative Resurfacing","A Prospective, Randomized, Open-label Study Evaluating the Efficacy of a Nanodiamond Periprocedural Skin Care Regimen for Ablative Resurfacing","Inclusion Criteria:\n\n1. Males or females in good general health age 35-70 years of age.\n2. Subjects with score Moderate to Severe (Class II-III, Score 4-9) on the Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale (Appendix E)\n3. Subjects with score Moderate to Severe facial photodamage as assessed by the Modified Griffth's Scale (Appendix F)\n4. Fitzpatrick skin types I-III.\n5. Must be willing to give and sign Informed Consent Form, Photography Release Form and HIPAA Form.\n6. The subject must be planning to undergo ablative CO2 and Er:YAG laser resurfacing to the face and willing to comply with study dosing and complete the entire course of the study.\n7. Subjects using any skin care products (per physician-investigator discretion) must discontinue use of these products 14 days before treatment and throughout the duration of the study. Subjects will only use the products they are instructed to use by the investigator.\n8. Male subjects with facial hair must be willing to shave the morning of the procedure\n9. Female patients will be either of non-childbearing potential defined as: Having no uterus or no menses for at least 12 months. Women of childbearing potential must agree to use an effective method of birth control during the study, such as:\n\n   1. Hormonal contraception - pill, injection, implant, patch, vaginal ring, Intrauterine device\n   2. Intrauterine coil\n   3. Bilateral tubal ligation\n   4. Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom)\n   5. Abstinence (If practicing abstinence must agree to use barrier method described above (4) if becomes sexually active).\n   6. Vasectomized partner (Must agree to use barrier method described above (4) if becomes sexually active with an Un-Vasectomized partner).\n   7. Negative urine pregnancy test results at Baseline prior to procedure (if applicable\n\nExclusion Criteria:\n\n1. Pregnant, planning to become pregnant during the course of the study, or breastfeeding.\n2. Prescence of an active bacterial, fungal, or viral infection in the treatment area.\n3. Significant history or current evidence of a medical, psychological or other condition that, in the investigator's opinion, would preclude enrollment into the study.\n4. Use of any topical products containing tretinoins or derivatives, alpha-hydroxy acids, salicylic acid, and vitamins C or E (includes derivatives thereof) on the face within 14 days prior to or during the study period, other than the study products.\n5. Receipt of a chemical peel, any systemic steroids, a non-ablative laser, ablative laser, microfocused ultrasound, light or radio frequency treatment, deep chemical peel, or dermabrasion on their face within 6 months prior to study enrollment.\n6. Receipt of a microdermabrasion (light or medium skin peel) treatment to the face within 30 days prior to enrollment and unwillingness to refrain from use for the duration of the study period.\n7. Excessive exposure to sunlight or artificial UV light (e.g.: use of tanning beds\u002Fbooths and\u002For sunbathing) or expectations of tanning during the time of the study or has used self-tanner within 7 days prior to enrollment.\n8. Prior treatment with a systemic retinoid within the past 3 months (e.g., Accutane®, Roche Dermatologics).\n9. History of keloids or hypertrophic scars.\n10. Known allergy to Valacyclovir or Fluconazole or sensitivities to benzocaine, lidocaine, tetracaine, PABA (para-amino benzoic acid), or other local anesthetics of the amide or ester family sedation medication.\n11. Presence of tattoo and\u002For scar in the treatment area that in the investigator's opinion would interfere with study assessments.\n12. History of or the presence of any skin condition\u002Fdisease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic dermatitis) at the discretion of the physician-investigator\n13. Inability to comply with all study protocol restrictions and visits.\n14. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.\n15. History of non-compliance with clinical research protocols.","ALL","35 Years","70 Years",{"count":61,"type":22},8,[63],"PHASE2","The primary objective of this study is to evaluate the efficacy and tolerability of Pavise Extracellular Matrix Restore (ECMR), compared with standard acute post-operative care, when used as the primary occlusive treatment immediately following ablative CO₂ and Er:YAG facial laser resurfacing to support wound healing.",[66],"Skin Laxity",[68,69,70,71],"face","rejuvenation","wrinkles","texture","2026-03-05",{"date":74,"type":41},"2026-03-10",{"date":76,"type":22},"2026-03-20",{"date":78,"type":22},"2026-08-30",{"name":47,"class":48},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":16,"sex":57,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":49},"100625354","phase-4-assess-injectable-hyaluronic-acid-gel-for-the-treatment-of-volume-loss-skin-laxity-and-fine-lines-100625354","NCT07421544","Assess Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines","A Prospective, Phase 4, Multicenter, Open-label Pilot Study of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines","Inclusion Criteria:\n\n1. Adult subjects aged 30 to 75 years at the time of screening\u002Fbaseline.\n2. Fitzpatrick skin types I-VI.\n3. Investigator classification of the subject as having mild-to-moderate facial aging in at least one (≥1) facial areas, defined as meeting the following scale criteria at screening\u002Fbaseline:\n\n   Midface Volume Deficit Scale (Appendix A): score of 2-3 Nasolabial Folds Severity Scale (Appendix B): score of 2 or 3\n4. Willing and able to comply with all study requirements, including scheduled visits, treatment protocol, and follow-up assessments.\n5. Willing and able to provide written informed consent form and photography release for research, publication, and\u002For commercial use.\n6. In good general health as determined by the investigator based on medical history and clinical judgment.\n7. Willing to maintain the study-specified skincare regimen and refrain from initiating new topical or procedural facial treatments during the study period.\n8. For subjects of childbearing potential, a negative urine pregnancy test at screening\u002Fbaseline and at all subsequent visits, as applicable.\n9. Female subjects of childbearing potential must agree to use an acceptable method of contraception throughout the study and must have been using systemic contraception consistently for at least 30 days prior to enrollment, unless they meet criteria for non-childbearing potential.\n\nSubjects are considered not of childbearing potential if they meet one of the following:\n\nHistory of hysterectomy or bilateral oophorectomy, or No menses for at least 12 consecutive months without an alternative medical cause.\n\nOr, if of childbearing potential, must agree to use an effective form of contraception during the course of the study. Acceptable methods include:\n\nOral contraceptive pill, injection, implant, patch, vaginal ring, or intrauterine device (IUD) Intrauterine coil Bilateral tubal ligation Hysterectomy Barrier method used with an additional form of contraception (e.g., spermicide, sponge, or condom) Abstinence (must agree to use a barrier method if sexual activity begins during the study) Partner with a vasectomy (if not, subject must agree to use a barrier methods\n\nExclusion Criteria:\n\n1. Prior use of injectable treatments to the face within the past 12 months, including HA fillers and biostimulator injectables, i.e. calcium hydroxyapatite, poly-L-lactic acid (e.g., Sculptra, Radiesse), platelet-rich plasma (PRP), platelet-rich fibrin (PRF) Any facial surgical procedure (e.g., facelift, facial implants) within the past 12 months.\n2. Use of neuromodulators (e.g., botulinum toxin) to the face or neck within 6 months prior to study enrollment or at any time during the study period.\n3. Use of dermal fillers of any kind during the study period.\n4. Use of at-home energy-based devices intended for rejuvenation or fibroblastic\u002Fcollagen stimulation within 30 days prior to treatment and during the study period.\n5. Use of systemic retinoids (e.g., isotretinoin) within 3 months prior to enrollment\n6. Active infection, open wounds, or inflammatory dermatoses (e.g., eczema, psoriasis, dermatitis) in the treatment area.\n7. Plants to become pregnant during the study period, or current breastfeeding.\n8. Known allergy or hypersensitivity to lidocaine, tetracaine, or other local anesthetics.\n9. Coagulation disorders or use of anticoagulants or antiplatelet medications that cannot be safely discontinued per investigator discretion.\n10. History of autoimmune connective tissue diseases (e.g., systemic lupus erythematosus, scleroderma, dermatomyositis).\n11. Current or recent use (within the past 3 months) of systemic immunosuppressive medications.\n12. Any uncontrolled systemic condition that may increase risk or interfere with study participation, including but not limited to poorly managed diabetes, thyroid dysfunction, or cardiovascular disease.\n13. Clinically significant neurological, psychological or psychiatric conditions, or any condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results.\n14. Current use of tobacco or nicotine-containing products, or use within 6 months prior to enrollment; participants must also agree to abstain from tobacco and nicotine-containing products for the duration of the study.\n15. Participation in any other interventional clinical study within 30 days prior to enrollment or during the course of this study.\n16. Unwillingness to refrain from undergoing any additional aesthetic treatments to the face and neck (e.g., lasers, injectables, energy-based devices, cosmeceuticals, etc.) from screening through the end of the study period.\n17. Use of sunless tanner or have spray tanned in the treatment areas 4 weeks prior to study treatment.\n18. History of keloids or scarring\u002Ftattoos in the treatment area.","30 Years","75 Years",{"count":90,"type":22},100,[92],"PHASE4","Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate facial aging, including volume loss, fine lines, and skin laxity, following treatment administered using routine clinical injection techniques over the course of 60 days.",[95,96,97,98],"Fine Lines","Wrinkle","Facial Laxity","Volume Loss","2026-02-12",{"date":101,"type":41},"2026-02-19",{"date":103,"type":22},"2026-03-01",{"date":105,"type":22},"2026-07-01",{"name":47,"class":48},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":16,"sex":57,"minAge":114,"maxAge":88,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":49},"100619268","phase-4-study-comparing-glycerin-with-1-lidocaine-and-epinephrine-versus-glycerin-with-1-lidocaine-without-epinephrine-for-the-sclerotherapy-of-leg-telangiectasias-100619268","NCT07342413","Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias","A Single-center Prospective Double-Blind, Split-Body, Randomized Clinical Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias","Inclusion Criteria:\n\n1. Subjects aged 20-75years.\n2. Fitzpatrick skin types I-VI.\n3. Presence of lower extremity telangiectatic veins (\\\u003C1 mm) suitable for sclerotherapy (reticular veins ≥1 mm can be present but are not required).\n4. Duplex ultrasonography negative for saphenous vein reflux in both legs.\n5. Willing to undergo split-leg randomization (CG + 1% lidocaine vs CG + 1% lidocaine with epinephrine 1:100,000).\n6. Willing and able to comply with all study procedures, including standardized photography, in-person evaluations by a non-treating physician investigator, Day 90 follow-up assessments, and post-treatment compression therapy consisting of graduated 30-40 mmHg stockings worn 24 hours\u002Fday for 1 week following treatment.\n7. Subject with no known history of coagulopathy\u002Fplatelet disorders (eg., hemophilia, von Willebrand disease) or liver disease\u002Fcirrhosis\n8. Subject with no history of hypercoagulable disorder such as pulmonary embolism, deep vein thrombosis, factor V Leiden mutation, Protein C or S deficiency, antiphospholipid syndrome, or active malignancy\n9. Subjects in good general health as determined by the investigator's judgment and medical history.\n10. Participants must be willing to provide written informed consent and sign a photography release for research and potential publication. Subjects must also agree to complete all study visits and procedures.\n11. Willing to avoid new lower-extremity aesthetic\u002Fvascular treatments (e.g., sclerotherapy, vascular lasers) and agree to avoid self-tanners or spray tans on the legs during the study period.\n12. Negative urine pregnancy test result at the time of study entry and all subsequent visits (if applicable)\n13. Subjects of childbearing potential must agree to use an effective method of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.\n\n    1. Acceptable forms of birth control are: oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device\u002Fcoil, bilateral tubal ligation, double-barrier methods (e.g., sponge, spermicide, or condoms). Abstinence and\u002For vasectomized partner must agree to a second acceptable method of birth control (double-barrier) should the subject become sexually active.\n    2. A female is considered of non-childbearing potential if she is: postmenopausal (no menses for at least 12 months\u002F≥ 12 months of amenorrhea without another medical cause), without a uterus (hysterectomy) and\u002For both ovaries (oophorectomy).\n\nExclusion Criteria:\n\n1. Positive duplex ultrasonography demonstrating saphenous vein reflux.\n2. Prior sclerotherapy or vascular laser treatment to the lower extremities within the past 6 months prior to screening\u002Fbaseline\n3. History of ulceration, thrombophlebitis, or deep vein thrombosis (DVT) in the lower extremities.\n4. Active infection, open wounds, or inflammatory dermatoses (e.g., eczema, psoriasis, dermatitis) in the treatment area.\n5. Known allergy or hypersensitivity to lidocaine, epinephrine, or glycerin.\n6. Any uncontrolled systemic condition that may increase risk or interfere with study participation (e.g., poorly managed diabetes, thyroid dysfunction, cardiovascular disease).\n7. Pregnancy, intent to become pregnant during the study period, or current breastfeeding.\n8. Clinically significant psychiatric or psychological conditions that, in the opinion of the investigator, may interfere with compliance or interpretation of results\n9. Participation in another clinical study within 30 days prior to enrollment of this study or during this study.\n10. Unwillingness to refrain from additional lower extremity aesthetic\u002Fvascular treatments (e.g., sclerotherapy, vascular lasers, self-tanning) from the screening\u002Fbaseline visit through the end of study.\n11. Unwillingness to follow a wash-out period of 4 weeks prior to screening for self-tanner application.\n12. Unwillingness to refrain from self-tanner application for 1 month prior to any visits.\n13. Unwillingness or inability to comply with post-treatment compression therapy consisting of graduated 30-40 mmHg stockings worn 24 hours\u002Fday for 1 week following treatment","20 Years",{"count":116,"type":22},20,[92],"The primary objective is to compare physician-assessed clearance of telangiectatic veins between treatment legs using the Physician Global Aesthetic Improvement Scale (PGAIS). Secondary objectives include assessment of procedural pain, safety outcomes, and patient satisfaction.",[120],"Leg Veins","2026-01-13",{"date":123,"type":41},"2026-01-15",{"date":125,"type":22},"2026-02-01",{"date":127,"type":22},"2026-07-30",{"name":47,"class":48},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":16,"sex":17,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":49},"100609967","phase-2-assess-impact-of-microdroplet-hyaluronic-acid-filler-on-skin-quality-in-patients-on-glucagon-like-peptide-1-agonists-100609967","NCT07221461","Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists","Prospective, Single Center, Open-label Study Assessing Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality and Biomarkers in Patients on Glucagon-like Peptide-1 Agonists","Inclusion Criteria:\n\n1. Adult women aged 25-50 years.\n2. Fitzpatrick skin types I-VI.\n3. Current treatment with a stable dose of GLP-1 agonist medication for at least the last 6 months, for 16 of the enrolled subjects. Remaining 8 subjects should not be taking or have a history of taking a GLP-1 agonist therapy in the last year.\n4. Presence of moderate skin changes (as defined by Modified Griffiths' Scale, with an average score of 4-6) in the following criteria: skin radiance\u002Fbrightness, skin elasticity, tone evenness, skin firmness, fine lines, global wrinkles, and skin smoothness (tactile and visual).\n5. Participants must maintain a stable weight, defined as no greater than a 10% weight change from screening\u002Fbaseline and throughout the study.\n6. Participants must have a body mass index (BMI) of 27 or less.\n7. Must be willing to sign a photography release and ICF, and complete the entire course of the study.\n8. Participant must agree to maintaining the same skincare routine they are currently using throughout the study period.\n9. Subjects in good general health based on investigator's judgment and medical history.\n10. Negative urine pregnancy test result at the time of study entry (if applicable).\n11. Females of childbearing potential must be willing to use an acceptable method of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.\n\n    1. 1\\. Acceptable methods of birth control are: oral contraceptive pill, injections, implants, patches, vaginal rings, intrauterine device\u002Fcoil, double-barrier methods (e.g., sponge, spermicide, or condoms). Abstinence and\u002For vasectomized partner must agree to a second acceptable method of birth control (double-barrier) should the subject become sexually active.\n    2. 2\\. A female is considered of non-childbearing potential if she is: postmenopausal (no menses for at least 12 months), without a uterus (hysterectomy) and\u002For both ovaries (oophorectomy), or bilateral tubal ligation.\n\nExclusion Criteria:\n\n1. The presence of severe facial skin aging (as defined by Modified Griffiths' Scale, with an average score of 7-9) or minimal facial skin aging (as defined by Modified Griffiths' Scale, with an average score of 0-3).\n2. Females who are pregnant, planning a pregnancy, or currently breast feeding during the study.\n3. Any uncontrolled systemic disease.\n4. History of autoimmune connective tissue disease.\n5. Current use of immunosuppressive medication.\n6. Weight change of greater than 10% during the study period.\n7. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.\n8. Active dermatitis (including but not limited to atopic dermatitis, psoriasis, rosacea, acne, melasma, etc.), active infections, or other skin condition in the proposed treatment area that in the investigator's opinion might interfere with the evaluation of study parameters.\n9. Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; laser and light-based device treatments; microneedling; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment. Botulinum toxin injections (Botox, Dysport, Xeomin, Daxify, Jeuveau) during the 6-month period before study treatment.\n10. Any investigational treatment for skin quality of the cheeks during the 12-month period before the study treatment.\n11. Creams\u002Fcosmeceuticals and\u002For home therapies for the prevention or treatment of skin fine lines, wrinkles, radiance, elasticity, firmness, or smoothness in the treatment area during the 4-week period before study treatment and throughout the course of the study.\n12. Subjects with scarring in the treatment areas. Subjects with a history of keloids will be excluded.\n13. Subjects who spray tanned or used sunless tanners in the treatment areas 4 weeks prior to study treatment.\n14. History of bleeding disorder, concomitant use of anticoagulants, history of connective tissue disease (e.g., lupus, scleroderma), history of Bell's Palsy, epilepsy, smoking, and\u002For current pregnancy or breastfeeding.\n15. Inability to ambulate following the procedure.\n16. History of lidocaine and\u002For tetracaine sensitivity deemed by the investigator to preclude subject from enrolling into study.\n17. Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study.\n18. Subjects planning any cosmetic procedure to the treatment area during the study period, other than the treatment that will be performed by the investigator.\n19. Use of topical steroids, retinoids\u002Fretinols, or vitamin C to the face within the previous 2-weeks of screening.\n20. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.","25 Years","50 Years",{"count":139,"type":22},24,[63],"Clinical trial to assess the effect of microdroplet hyaluronic acid filler to the cheek skin (SKINVIVE™, JUVÉDERM®, Irvine, CA) on skin quality in patients undergoing medical weight loss with GLP-1 therapy.",[96],[34,144,145,146],"fine lines","dull skin","uneven skin tone","2025-10-24",{"date":149,"type":41},"2025-10-28",{"date":151,"type":22},"2025-11-01",{"date":153,"type":22},"2026-03-02",{"name":47,"class":48},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":16,"sex":57,"minAge":136,"maxAge":137,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":167,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":49},"100609574","evaluate-the-safety-and-efficacy-of-a-topical-serum-age-serum-in-improving-visible-signs-of-aging-100609574","NCT07216352","Evaluate the Safety and Efficacy of a Topical Serum (AGE Serum) in Improving Visible Signs of Aging","Open-label Study Evaluating the Safety and Efficacy of AGE Serum in Non-menopausal Patients on Glucagon-like Peptide-1 Agonists","Inclusion Criteria:\n\n1. Presence of mild to moderate signs of facial aging (e.g., fine lines, laxity, dull texture) based on modified Griffith scale.\n2. Adult men and women aged 25-50 years.\n3. Fitzpatrick skin types I-IV.\n4. Current treatment with a stable dose of GLP-1 agonist medication, including Ozempic, Rybelsus, or Wegovy for at least last 6 months.\n5. Must be willing to sign a photography release and ICF, and complete the entire course of the study.\n6. Subjects in good general health based on the investigator's judgment and medical history.\n7. Negative urine pregnancy test result at the time of study entry (if applicable).\n8. Subjects of childbearing potential must agree to use an effective method of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.\n\nA. Acceptable forms of birth control are: oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device\u002Fcoil, double-barrier methods (e.g., sponge, spermicide, or condoms). Abstinence and\u002For vasectomized partners must agree to a second acceptable method of birth control (double-barrier) should the subject become sexually active.\n\nB. A female is considered of non-childbearing potential if she is: postmenopausal (no menses for at least 12 months), without a uterus (hysterectomy) and\u002For both ovaries (oophorectomy), or bilateral tubal ligation.\n\nExclusion Criteria:\n\n1. Pregnancy or planned pregnancy during the study or currently breastfeeding.\n2. Current menopausal state.\n3. Any uncontrolled systemic disease.\n4. Current use of other GLP-1 agonist therapy aside from the GLP-1 agonist class of medications (Ozempic, Rybelsus, or Wegovy).\n5. History of autoimmune connective tissue disease.\n6. Current use of immunosuppressive medication.\n7. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.\n8. Active dermatitis or active infection in the proposed treatment area.\n9. Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; laser and light-based device treatments; microneedling; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment.\n10. Creams\u002Fcosmeceuticals and\u002For home therapies for the prevention or treatment of skin quality in the treatment area during the 1-month period before study treatment.\n11. Subjects with scarring in the treatment areas, which in the opinion of the investigator could impact results. Subjects with a history of keloids will be excluded.\n12. Subjects who spray tanned or used sunless tanners in the treatment areas 1-month prior to study treatment.\n13. History of bleeding disorder, concomitant use of anticoagulants, history of connective tissue disease (e.g., lupus, scleroderma), history of Bell's Palsy, epilepsy, smoking, and\u002For current pregnancy or breastfeeding.\n14. Inability to ambulate following the procedure.\n15. History of lidocaine and\u002For epinephrine sensitivity deemed by the investigator to preclude subject from enrolling into study.\n16. Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study.\n17. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.",{"count":163,"type":22},25,[25],"The primary objective is to evaluate the safety and efficacy of a topical serum (AGE serum) in improving visible signs of aging (e.g., fine lines, wrinkles, sagging, texture, radiance) on the full face and neck.The study will be conducted in non-menopausal female and male subjects who are on glucagon-like peptide-1 (GLP-1) agonist therapy for weight loss.",[28],[168,33,34,35,36],"glp1",{"date":149,"type":41},{"date":171,"type":22},"2025-10-25",{"date":173,"type":22},"2026-05-30",{"name":47,"class":48},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":16,"sex":17,"minAge":136,"maxAge":19,"enrollmentInfo":182,"targetDuration":4,"studyType":23,"phases":183,"briefSummary":184,"conditions":185,"keywords":186,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":49},"100609681","phase-2-assess-impact-of-poly-l-lactic-acid-on-glp1-subjects-100609681","NCT07217743","Assess Impact of Poly-L-lactic Acid on GLP1 Subjects","Prospective, Single Center, Open-label Study Assessing Impact of Poly-L-lactic Acid on Adipogenesis in Patients on Glucagon-like Peptide-1 Agonists","Inclusion Criteria:\n\n1. Adult women aged 25-65 years.\n2. Fitzpatrick skin types I-IV.\n3. Presence of mild to moderate skin laxity of abdomen, as determined by clinical investigators.\n4. Stable weight for 3 months, with body mass index (BMI) of 27 or less.\n5. Current treatment with a stable dose of GLP-1 agonist medication for at least the last 6 months, for 15 of the enrolled subjects. Remaining 5 subjects should not be taking or have a history of taking a GLP-1 agonist medication, and should not be planning to take a GLP-1 in the foreseeable future.\n6. Must be willing to sign a photography release and ICF, and complete the entire course of the study.\n7. Subjects in good general health based on investigator's judgment and medical history.\n8. Negative urine pregnancy test result at the time of study entry (if applicable).\n9. Subjects of childbearing potential must agree to use an effective method of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.\n\n   1. Acceptable forms of birth control are: oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device\u002Fcoil, double-barrier methods (e.g., sponge, spermicide, or condoms). Abstinence and\u002For vasectomized partner must agree to a second acceptable method of birth control (double-barrier) should the subject become sexually active.\n   2. A female is considered of non-childbearing potential if she is: postmenopausal (no menses for at least 12 months), without a uterus (hysterectomy) and\u002For both ovaries (oophorectomy), or bilateral tubal ligation.\n\nExclusion Criteria:\n\n1. The presence of severe abdominal skin laxity as determined by clinical investigators.\n2. Still actively losing weight.\n3. Pregnancy or planned pregnancy during the study or currently breastfeeding.\n4. Any uncontrolled systemic disease.\n5. History of autoimmune connective tissue disease.\n6. Current use of immunosuppressive medication.\n7. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.\n8. Active dermatitis or active infection in the proposed treatment area.\n9. Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; laser and light-based device treatments; microneedling; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment.\n10. Any investigational treatment for skin quality of the abdomen during the 12-month period before the study treatment\n11. Creams\u002Fcosmeceuticals and\u002For home therapies for the prevention or treatment of skin quality in the treatment area during the 1-month period before study treatment\n12. Subjects with scarring in the treatment areas, including laparoscopic or abdominal surgery scars, which in the opinion of the investigator could impact results. Subjects with a history of keloids will be excluded.\n13. Subjects who spray tanned or used sunless tanners in the treatment areas 1-month prior to study treatment.\n14. History of bleeding disorder, concomitant use of anticoagulants, history of connective tissue disease (e.g., lupus, scleroderma), history of Bell's Palsy, epilepsy, smoking, and\u002For current pregnancy or breastfeeding .\n15. Inability to ambulate following the procedure.\n16. History of lidocaine and\u002For epinephrine sensitivity deemed by the investigator to preclude subject from enrolling into study.\n17. Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study.\n18. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.",{"count":116,"type":22},[63],"Clinical trial to evaluate treatments of double-dilute poly-L-lactic acid on abdominal skin laxity in GLP1 patients versus non GLP1 patients.",[28],[187,188,168,189],"laxity","loose skin","abdominal laxity","2025-10-14",{"date":192,"type":41},"2025-10-16",{"date":194,"type":22},"2025-10-27",{"date":196,"type":22},"2026-10-31",{"name":47,"class":48},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":16,"sex":17,"minAge":58,"maxAge":19,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":49},"100587256","1550nm-non-ablative-fractional-vs-1927nm-thulium-fractional-laser-for-the-treatment-of-female-pattern-hair-loss-100587256","NCT06926023","1550nm Non-ablative Fractional Vs 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss","A Prospective, Randomized, Evaluator-blind, Clinical Trial Evaluating the 1550nm Non-ablative Fractional or 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss","Inclusion Criteria:\n\n1. Adult women aged 35-65 years\n2. Fitzpatrick skin types I-IV\n3. Presence of female pattern hair loss of the frontal or vertex of scalp (Sinclair (II-IV)\n4. Must be willing and can comply with all study protocols, including all treatment schedules, follow up visit, assessments, sign a photography release and ICF, and complete the entire course of the study\n5. Patients with gray hair roots must be willing to dye their gray hair within two weeks of the first appointment and the last 3-month follow-up visit to ensure consistency in evaluator assessments.\n6. No use of hair growth treatments or procedures within 6 months prior to enrollment (including hair supplements such as Nutrafol)\n7. Subjects in good general health based on investigator's judgment and medical history\n8. Negative urine pregnancy test result at the time of study entry\n9. Subjects will be of non-childbearing potential defined as:\n10. Having no uterus\n11. No menses for at least 12 months.\n12. Or;\n13. Subjects of childbearing potential must agree to use an effective method of birth control during the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment participation. Acceptable forms of birth control below:\n14. Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device\n15. Intrauterine coil\n16. Bilateral tubal ligation\n17. Hysterectomy\n18. Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom)\n19. Abstinence (If practicing abstinence must agree to use barrier method described above (4) if becomes sexually active).\n20. Vasectomized (must agree to use barrier method described above (4) if becomes sexually active with un-vasectomized partner).\n\nExclusion Criteria:\n\n1. No surgery, pregnancy, breast feeding, change in or addition of hormonal contraception in the last 6 months\n2. No history of iron deficiency anemia, vitamin D deficiency, or thyroid disease (hypothyroidism or hyperthyroidism or currently on thyroid supplementation)\n3. Use of scalp light or with laser treatment within the last 6 months.\n4. Use of topical or systemic drugs affecting hair growth within 6 months prior to enrollment (such as oral spironolactone, finasteride, oral or topical minoxidil, and supplements marketed for hair growth such as Nutrafol)\n5. Supplementation of oral tumeric\u002Fcurcumin\n6. History of hair transplant\n7. Systemic or scalp disease that may affect hair growth (Lupus, alopecia areata, folliculitis decalvans, psoriasis, scalp infection, seborrheic dermatitis, CCCA, telogen effluvium)\n8. Pregnancy or planned pregnancy during the study or currently breastfeeding.\n9. Any uncontrolled systemic disease\n10. History of autoimmune connective tissue disease or thyroid disease.\n11. Current use of immunosuppressive medication.\n12. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.\n13. Active dermatitis, metal or other active implants, active infection in the proposed treatment area.\n14. Subjects with scarring in the treatment areas (scalp) Subjects with a history of keloids will be excluded.\n15. History of bleeding disorder, concomitant use of anticoagulants, history of connective tissue disease, history of Bell's Palsy, epilepsy, smoking, pregnancy, and lactation.\n16. Inability to following the comply with study protocols and regulations\n17. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.",{"count":5,"type":22},[25],"To evaluate the efficacy of either a 1550nm non-ablative fractional laser or a 1927nm thulium fractional laser in the treatment of female pattern hair loss (FPHL).",[209],"Female Pattern Baldness","2025-04-11",{"date":212,"type":41},"2025-04-16",{"date":214,"type":22},"2025-05-01",{"date":216,"type":22},"2025-12-31",{"name":47,"class":48},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":16,"sex":57,"minAge":225,"maxAge":137,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":228,"briefSummary":230,"conditions":231,"keywords":234,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":4},"100565186","phase-2-efficacy-and-safety-of-skincare-serum-and-cream-for-anti-aging-of-facial-skin-100565186","NCT06638905","Efficacy and Safety of Skincare Serum and Cream for Anti-aging of Facial Skin","A Prospective, Open Label Clinical Study Evaluating the Efficacy and Safety of Skincare Serum and Cream for Anti-aging of Facial Skin","Inclusion Criteria:\n\n* Men and women between the ages of 18 and 50 years old (inclusive).\n* Subjects must be able and willing to provide written informed consent and photography release.\n* At the baseline evaluation, all subjects must exhibit mild to moderate skin aging, as defined below (Appendix A):\n\n  1. Class I-II of Wrinkling on the Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale\n  2. Score 1-6 of Degree of Elastosis on the Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale\n  3. Mild to Moderate on Redness\u002FErythema Grading Scale\n  4. Mild to Moderate on Dryness\u002FScaling\u002FRoughness Grading Scale\n  5. Mild to Moderate on Luminosity Scale\n* Subject must be in good general health with no other skin disease, disease state or physical condition which would impair evaluation of the areas to be treated or which would increase the subject's health risk by study participation.\n* Subjects must have a willingness to minimize sun exposure, avoid direct sun exposure on the face, and avoid the use of tanning beds for the entire duration of the study. Must be willing to wear a hat and reapply sunscreen if sun exposure is unavoidable.\n* Subjects must be willing and able to understand and comply with the requirements of the study including prolonged sun exposure and apply the products as instructed, return for the required treatment period visits, comply with therapy prohibitions, and be able to complete the study\n* For female subjects of childbearing potential, must be willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.\n\n  1. A female is considered of childbearing potential unless she is postmenopausal, without a uterus and\u002For both ovaries, or has had a bilateral tubal ligation.\n  2. Acceptable methods of birth control are: oral contraceptives, contraceptive patches\u002Frings\u002Fimplants, Implanon®, Depo-Provera®, double-barrier methods (e.g., condoms and spermicide), abstinence, and\u002For vasectomy of partner with a documented second acceptable method of birth control, should the subject become sexually active.\n\nExclusion Criteria:\n\n* Subjects who are pregnant, planning pregnancy during the course of the study, or breastfeeding.\n* Subjects with an active bacterial, fungal, or viral infection in the treatment area\n* Subjects with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.\n* Subjects receiving any topical products containing tretinoins or derivatives, alpha-hydroxy acids, salicylic acid, and vitamins C or E (includes derivatives thereof) on the face within 14 days prior to or during the study period, other than the study products.\n* Subjects receiving a chemical peel, any systemic steroids, a non-ablative laser, ablative laser, microfocused ultrasound, light or radio frequency treatment, deep chemical peel, and\u002For has had a Dermabrasion on their face must have discontinued the drug\u002Ftreatment and\u002For had the procedure at least 6 months prior to entering the study.\n* Subjects who have had a microdermabrasion (light or medium skin peel) treatment on their face within 30 days prior to and not willing to refrain from use for the duration of the study period.\n* Subjects with recently excessive exposure to sunlight or artificial UV light (e.g.: use of tanning beds\u002Fbooths and\u002For sunbathing) or expectations of tanning during the time of the study or has used self-tanner within 7 days of study entry.\n* Subjects that has previously been treated with a systemic retinoid within the past 3 months (e.g., Accutane®, Roche Dermatologics).\n* Subjects with a history of keloids or hypertrophic scars.\n* Subjects with known allergies to any of the product ingredients.\n* Subjects with a tattoo and\u002For scar in the treatment area that in the investigators opinion would interfere with study assessments.\n* Subjects with history of or the presence of any skin condition\u002Fdisease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic dermatitis) at the discretion of the investigator.\n* Inability to comply with all study protocol restrictions and visits.\n* Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.\n* History of non-compliance with clinical research protocols.","18 Years",{"count":227,"type":22},18,[63,229],"PHASE3","The primary objective of this study is to assess the efficacy and safety of combination therapy of BABOR® Ultimate ECM Repair Serum and the BABOR® Cure Cream for the improvement of anti-aging through the use of investigator assessments, subject questionnaires\u002Fassessments, photography, skin imaging, and reported adverse reactions.",[232,233],"Facial Wrinkles","Skin Aging",[235,236,237,238],"Wrinkles","Face Wrinkles","Cosmetic","Crow's Feet","2024-10-09",{"date":241,"type":41},"2024-10-15",{"date":243,"type":22},"2024-10-28",{"date":245,"type":22},"2025-05-05",{"name":47,"class":48},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":57,"minAge":87,"maxAge":59,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":256,"briefSummary":257,"conditions":258,"keywords":260,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":49},"100562491","phase-2-skin-care-regimen-for-improving-photoaging-signs-on-the-face-100562491","NCT06603857","Skin Care Regimen for Improving Photoaging Signs on the Face","A Prospective, Placebo-controlled, Double-blinded, Randomized Clinical Trial Evaluating the Efficacy and Tolerability of Pre and Post Care Skincare Regimen Paired With 1927nm Diode Fractional Laser for Photodamage on the Face","Inclusion Criteria:\n\n* Adult males and females aged 30-70 years (Fitzpatrick I-IV 30-65 years, Fitzpatrick V-VI 30-70 years)\n* Fitzpatrick skin types I-VI\n* Subjects in good general health based on investigator's judgment and medical history\n* Must be willing to give and sign an informed consent form and photographic release form\n* Must be willing to have examinations of face and digital photographs performed of the face\n* Physician evaluator classifying the subject as mild to moderate (Score 3-6) on the modified Griffiths 10-Point Scale for the face.\n* The subject must be planning to undergo fractional non-ablative laser resurfacing to the face and bilateral postauricular area and be willing to comply with study protocol and complete the entire course of the study.\n* Subjects using any treatment skincare products (per investigator discretion) must discontinue use of these products four weeks before the start of participating in this clinical study and for the duration of the study.\n* Male subjects with facial hair must be willing to shave prior to every visit.\n* Must be willing to maintain usual sun exposure\n* Subject agrees to avoid tanning or use of sunless tanner during the entire course of the study\n* Negative urine pregnancy test result at the time of study entry (if applicable)\n* For female subjects of childbearing potential, must be willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.\n* A female is considered of childbearing potential unless she is postmenopausal, without a uterus and\u002For both ovaries, or has had a bilateral tubal ligation.\n* Acceptable methods of birth control are: oral contraceptives, contraceptive patches\u002Frings\u002Fimplants, Implanon®, Depo-Provera®, double-barrier methods (e.g., condoms and spermicide), abstinence, and\u002For vasectomy of partner with a documented second acceptable method of birth control, should the subject become sexually active.\n* Must be willing to comply with study treatments and complete the entire course of the study\n\nExclusion Criteria:\n\n* Energy-based device (i.e., radiofrequency device treatments, microfocused ultrasound device or other ultrasound-based device treatments, laser and light-based device treatments, microneedling) treatment in the treatment area in the last 6 months\n* Chemical peel or microdermabrasion of the face within 60 days prior to enrollment in the study\n* Dermal fillers, biostimulators, or neurotoxins treatments of the face during the 6-month period before the study period or planning to undergo during the study period\n* Surgery (i.e., face lift, eyebrow lift, neck lift or lower rhytidectomy, liposuction to the neck and\u002For submentum, etc.) during the 12-month period before study treatment\n* Any investigational treatment for improvement of skin quality and\u002For photodamage of facial skin during the 6-month period before the study treatment\n* Use of topical steroids, tretinoin, adapalene, tazarotene, hydroquinone, imiquimod, 5-fluorouracil, ingenol mebutate, concentrated hydrogen peroxide, diclofenac, or photodynamic therapy (PDT) to the face within the previous 4 weeks\n* Subjects must not currently be taking isotretinoin (Accutane).\n* Creams\u002Fcosmeceuticals and\u002For home therapies to prevent or treat photodamage, uneven skin pigmentation, excessive erythema (redness), fine lines\u002Fwrinkles, skin laxity and\u002For pore size during the 4-week period before study treatment\n* Subjects with scarring in the treatment areas\n* Subjects with tattoos in the treatment areas\n* Subjects with a significant history or current evidence of a medical, psychological, or other disorder that, in the investigator's opinion, would preclude enrollment into the study\n* Subjects with a history of or presence of any skin condition\u002Fdisease (including but not limited to any visible rash, atopic dermatitis, psoriasis, actinic keratoses, keratinocyte carcinoma, melanoma, etc.) in the treatment area that might interfere with the diagnosis or evaluation of study parameters\n* Skin with open wounds, excessively sensitive skin, neurotic excoriations, dermatitis or inflammatory rosacea in the treatment area\n* History of keloid or hypertrophic scarring\n* Subjects with an active bacterial, viral, or fungal infection of the treatment areas or systemic infection\n* Subjects who spray tanned or used sunless tanners in the treatment areas four (4) weeks prior to study treatment\n* History of lidocaine and\u002For tetracaine sensitivity deemed by the investigator to preclude the subject from enrolling into the study\n* Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study\n* Subjects must not have a compromised ability for wound healing, such as:\n\nmalnutrition, steroid use, history of collagen vascular disease (e.g., lupus, scleroderma), atopic dermatitis, or immunologic abnormalities such as vitiligo.\n\n* Subjects planning any cosmetic procedure to the treatment areas during the study period, other than the treatment that will be performed by the investigator\n* Presence of incompletely healed wound(s) in the treatment area\n* Subjects who are on an immunosuppressant or have an autoimmune condition\n* Female subjects who are pregnant, planning a pregnancy, or breast feeding during the study\n* Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study",{"count":255,"type":22},40,[63,229],"Compare the effectiveness of laser treatment using CE Ferulic versus vehicle pre\u002Fpost laser.",[259],"Improve Photoaging Signs",[70,261,262],"aging","photodamage","2024-09-16",{"date":265,"type":41},"2024-09-19",{"date":267,"type":22},"2024-09-27",{"date":269,"type":22},"2025-02-28",{"name":47,"class":48},""]